Strengths
- Public sources support Redesign Health's private-unicorn screening status at $1.70B.
- Redesign Health publicly markets active products/services.
- Redesign Health has current operating/personnel signals.
Diligence report
Redesign Health
Redesign Health Startup Diligence Report
Redesign Health appears active and still privately held, with public evidence of unicorn status, portfolio scale, institutional partners and an AI-native venture-building strategy. Underwriting depends on parent economics, portfolio ownership, partner contracts and regulatory risk allocation.
Company profile
Redesign Health Startup Diligence Report
Proceed only with a data-room-led diligence path; public evidence supports activity and scale, but the economically material facts sit in fund documents, portfolio financials and contracts.
- Website
- www.redesignhealth.com
- Sector
- Healthcare venture creation, applied technology and AI-native company building
- Geography
- United States / New York with global healthcare partnerships
- Stage
- Private unicorn / Series C healthcare venture builder
- Known aliases
- Redesign Health, Redesign Health Inc.
- Report version
- 1.0
- Timezone
- UTC
Executive summary
Risks
- Studio economics and portfolio valuation opacity
- Healthcare regulatory and clinical-liability dispersion
- Partner-logo dependency and concentration risk
Gaps
- Audited financials, ARR/bookings, gross margin, cash, debt and forecast model
- Cap table, preferences, options, warrants, notes and investor rights
- Top-customer revenue, contracts, renewal, churn and NRR cohorts
- CAC, pipeline, quota attainment, sales cycle and payback
- Architecture, security, data provenance, roadmap and technical debt
Risk register
R-002: Healthcare regulatory and clinical-liability dispersion
Healthcare regulatory and clinical-liability dispersion is material because public evidence does not fully verify current economics, obligations or risk controls.
Diligence request: Request primary documents, third-party confirmations and specialist review before underwriting.
R-001: Studio economics and portfolio valuation opacity
Studio economics and portfolio valuation opacity is material because public evidence does not fully verify current economics, obligations or risk controls.
Diligence request: Request primary documents, third-party confirmations and specialist review before underwriting.
R-003: Partner-logo dependency and concentration risk
Partner-logo dependency and concentration risk is material because public evidence does not fully verify current economics, obligations or risk controls.
Diligence request: Request primary documents, third-party confirmations and specialist review before underwriting.
R-004: AI venture thesis execution risk
AI venture thesis execution risk is material because public evidence does not fully verify current economics, obligations or risk controls.
Diligence request: Request primary documents, third-party confirmations and specialist review before underwriting.
01Financial Information
Public evidence supports Redesign Health's unicorn screening status and financing anchors, but audited financials, ARR, margin, cash, debt and cap-table terms are private.
I.A Annual and quarterly financial information for the past three years
not publicly verifiable confidence: low
Public evidence supports Redesign Health's unicorn screening status and financing anchors, but audited financials, ARR, margin, cash, debt and cap-table terms are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Annual and quarterly financial information for the past three years.
I.B Financial Projections
unverified confidence: medium
Public evidence supports Redesign Health's unicorn screening status and financing anchors, but audited financials, ARR, margin, cash, debt and cap-table terms are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Financial Projections.
I.C Capital Structure
not publicly verifiable confidence: low
Public evidence supports Redesign Health's unicorn screening status and financing anchors, but audited financials, ARR, margin, cash, debt and cap-table terms are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Capital Structure.
| item | public evidence | diligence request | verification status |
|---|---|---|---|
| Shares/options/preferences | No complete public cap table found | Cap table, option plan, SAFEs/notes and investor rights | not_publicly_verifiable |
| Revenue/ARR/margin/cash | Public product or scale signals only | Audited financials, KPI pack, ARR bridge, gross margin, cash runway | not_publicly_verifiable |
| Debt/off-balance-sheet liabilities | Series C | Alive per CB Insights profile | Debt agreements, covenants, leases, guarantees and vendor commitments | not_publicly_verifiable |
I.D Other financial information
partially verified confidence: medium
Public evidence supports Redesign Health's unicorn screening status and financing anchors, but audited financials, ARR, margin, cash, debt and cap-table terms are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Other financial information.
| date | event | amount or round | valuation | source | verification status |
|---|---|---|---|---|---|
| 2022-09-13 | Unicorn-list valuation row | not disclosed in list row | $1.70B | CB Insights unicorn list | verified |
| latest public profile fetch | Series C | Alive per CB Insights profile | $415M per CB Insights profile; 2024 reporting describes a $175M fund and prior Series C at $1.7B post-money valuation | $1.70B | CB Insights profile / public news | partially_verified |
| diligence request | Current primary valuation support | not publicly verifiable | not publicly verifiable | cap table and financing documents | not_publicly_verifiable |
02Products
Public product/service pages describe Redesign Health's offering, but product-level economics require private proof.
II.A Description of each product
partially verified confidence: medium
Public product/service pages describe Redesign Health's offering, but product-level economics require private proof.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Description of each product.
| product | description | public evidence | verification status |
|---|---|---|---|
| Venture creation platform | Healthcare company-building model for founders, partners and investors | Company-owned and profile sources | partially_verified |
| AI-native operating system | Knowledge graph and applied technology infrastructure | Company-owned and profile sources | partially_verified |
| Healthcare venture partnerships | Programs with institutions such as Cedars-Sinai and displayed ecosystem logos | Company-owned and profile sources | partially_verified |
| Portfolio support and capital formation | Fund and platform support for new healthcare ventures | Company-owned and profile sources | partially_verified |
| pricing item | public signal | diligence gap |
|---|---|---|
| Public pricing | Not disclosed or quote-based in fetched public sources | ARR, ACV, discounts, implementation costs and gross margin |
| Value claims | Public ROI/customer/scale claims where available | Customer-specific realized value and payback validation |
| Competitor pricing | Not comparable from public sources | Like-for-like deal benchmarking |
03Customer Information
Public customer and partner signals exist, but top-customer revenue, renewals, churn and concentration are not public.
III.A Top customers by application
partially verified confidence: medium
Public customer and partner signals exist, but top-customer revenue, renewals, churn and concentration are not public.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Top customers by application.
| customer or segment | public evidence | revenue gap |
|---|---|---|
| Portfolio founders/companies | More than 60 health-tech companies launched since 2018 per MobiHealthNews | ARR, contract terms, renewal health and concentration are not public |
| Patients touched through portfolio | Company says portfolio touched more than 15M patients | ARR, contract terms, renewal health and concentration are not public |
| Cedars-Sinai | Collaboration on digital health venture / technology-transfer platform | ARR, contract terms, renewal health and concentration are not public |
| Institutional partners | Homepage displays Anthropic, AWS, Cedars-Sinai, DaVita, General Catalyst, Google, Mayo Clinic, Microsoft, OpenAI, Sanabil and UPMC logos | ARR, contract terms, renewal health and concentration are not public |
III.B Strategic relationships
partially verified confidence: medium
Public customer and partner signals exist, but top-customer revenue, renewals, churn and concentration are not public.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Strategic relationships.
| partner or supplier | role | contract gap |
|---|---|---|
| General Catalyst/CVS/UPMC/Samsung NEXT | Investor and ecosystem partner signals | Contract value, exclusivity, termination rights and operational dependence are private |
| Cedars-Sinai | Technology-transfer / digital venture collaboration | Contract value, exclusivity, termination rights and operational dependence are private |
| Anthropic/AWS/Google/Microsoft/OpenAI | Technology partner logos; contract terms not public | Contract value, exclusivity, termination rights and operational dependence are private |
III.C Revenue by customer
not publicly verifiable confidence: low
Public customer and partner signals exist, but top-customer revenue, renewals, churn and concentration are not public.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Revenue by customer.
III.D Significant relationships severed within the last two years
unverified confidence: medium
Public customer and partner signals exist, but top-customer revenue, renewals, churn and concentration are not public.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Significant relationships severed within the last two years.
III.E Top suppliers
unverified confidence: medium
Public customer and partner signals exist, but top-customer revenue, renewals, churn and concentration are not public.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Top suppliers.
04Competition
Competitors are identifiable, but win/loss, pricing pressure and defensibility require customer and deal evidence.
IV.A Competitive landscape by market segment
partially verified confidence: medium
Competitors are identifiable, but win/loss, pricing pressure and defensibility require customer and deal evidence.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Competitive landscape by market segment.
| competitor | overlap | differentiator to verify |
|---|---|---|
| Define Ventures/Rock Health/healthcare venture platforms | Direct or adjacent competition for buyers, budgets, talent or data/AI capability | Win/loss, pricing, retention and reference calls |
| Thirty Madison | Direct or adjacent competition for buyers, budgets, talent or data/AI capability | Win/loss, pricing, retention and reference calls |
| Maven | Direct or adjacent competition for buyers, budgets, talent or data/AI capability | Win/loss, pricing, retention and reference calls |
| Spring Health/Lyra | Direct or adjacent competition for buyers, budgets, talent or data/AI capability | Win/loss, pricing, retention and reference calls |
| Health-system innovation offices | Direct or adjacent competition for buyers, budgets, talent or data/AI capability | Win/loss, pricing, retention and reference calls |
| axis | public signal | risk or test |
|---|---|---|
| Product breadth | Multiple products/services publicly described | Verify module adoption and margins |
| Technical/data depth | Public R&D/IP/data signals exist | Review architecture, data rights, security and benchmarks |
| Distribution/trust | Named customers, partners or investor logos | Validate contracts and referenceability |
| Price/value | Pricing not fully public | Benchmark ACV, discounts and payback |
05Marketing, Sales, and Distribution
Public channels show positioning and GTM motions, but CAC, funnel conversion, quota attainment and budget capacity are private.
V.A Strategy and implementation
partially verified confidence: medium
Public channels show positioning and GTM motions, but CAC, funnel conversion, quota attainment and budget capacity are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Strategy and implementation.
| channel | public evidence | gap |
|---|---|---|
| Founder and venture sourcing | Visible from company pages, news or profile context | CAC, funnel conversion, sales cycle, quota attainment and budget are private |
| Health-system collaborations | Visible from company pages, news or profile context | CAC, funnel conversion, sales cycle, quota attainment and budget are private |
| Investor/LP and partner network | Visible from company pages, news or profile context | CAC, funnel conversion, sales cycle, quota attainment and budget are private |
| Thought leadership and news | Visible from company pages, news or profile context | CAC, funnel conversion, sales cycle, quota attainment and budget are private |
V.B Major Customers
unverified confidence: medium
Public channels show positioning and GTM motions, but CAC, funnel conversion, quota attainment and budget capacity are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Major Customers.
V.C Principal avenues for generating new business
partially verified confidence: medium
Public channels show positioning and GTM motions, but CAC, funnel conversion, quota attainment and budget capacity are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Principal avenues for generating new business.
| signal | evidence | diligence request |
|---|---|---|
| Company-owned web/resources | Current product, customer, careers and news pages | Web analytics and lead attribution |
| Third-party profiles/news | CB Insights and independent/search snippets | Press impact and inbound pipeline |
| Customer/partner credibility | Named customers/partners/logos where available | Reference calls and contract validation |
V.D Sales force productivity model
not publicly verifiable confidence: low
Public channels show positioning and GTM motions, but CAC, funnel conversion, quota attainment and budget capacity are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Sales force productivity model.
V.E Ability to implement marketing plan with current and projected budgets
unverified confidence: medium
Public channels show positioning and GTM motions, but CAC, funnel conversion, quota attainment and budget capacity are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Ability to implement marketing plan with current and projected budgets.
06Research and Development
Public R&D/IP/data signals exist, but roadmap, technical debt, security posture and development cost require diligence.
VI.A Description of R&D organization
partially verified confidence: medium
Public R&D/IP/data signals exist, but roadmap, technical debt, security posture and development cost require diligence.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Description of R&D organization.
| signal | public evidence | diligence request |
|---|---|---|
| AI knowledge graph | Public page/profile evidence | Roadmap, staffing, spend, technical debt, security review and ownership files |
| AI/genAI healthcare venture themes | Public page/profile evidence | Roadmap, staffing, spend, technical debt, security review and ownership files |
| 1 patent listed by CB Insights | Public page/profile evidence | Roadmap, staffing, spend, technical debt, security review and ownership files |
VI.B New Product Pipeline
partially verified confidence: medium
Public R&D/IP/data signals exist, but roadmap, technical debt, security posture and development cost require diligence.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for New Product Pipeline.
| pipeline area | public status | risk |
|---|---|---|
| Core offering evolution | Active public roadmap/product themes | Roadmap may not convert to adoption or margin |
| Security/compliance readiness | Public evidence varies by company | Enterprise/healthcare/data buyers require auditable controls |
| Market expansion | Markets/partners referenced publicly | Expansion may increase burn or regulatory complexity |
07Management and Personnel
Personnel or hiring signals are visible, but org chart, headcount history, turnover, compensation and key-person risk are private.
VII.A Organization Chart
unverified confidence: medium
Personnel or hiring signals are visible, but org chart, headcount history, turnover, compensation and key-person risk are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Organization Chart.
VII.B Historical and projected headcount by function and location
partially verified confidence: medium
Personnel or hiring signals are visible, but org chart, headcount history, turnover, compensation and key-person risk are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Historical and projected headcount by function and location.
| signal | public evidence | gap |
|---|---|---|
| Careers page | Active openings across Platform, Strategy & Finance and Ventures | Need HRIS export, attrition, function/location headcount and compensation bands |
| People page | Large roster visible but roles not fully disclosed | Need HRIS export, attrition, function/location headcount and compensation bands |
| Portfolio staffing | Distributed across portfolio companies; private | Need HRIS export, attrition, function/location headcount and compensation bands |
VII.C Senior management biographies
partially verified confidence: medium
Personnel or hiring signals are visible, but org chart, headcount history, turnover, compensation and key-person risk are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Senior management biographies.
| name or role | role | public evidence |
|---|---|---|
| Neil Patel | Head of ventures quoted by MobiHealthNews | Public page/news source; verify tenure, reporting lines and references |
| Managing Director of New Ventures roles | Active openings in New York, San Francisco and Cedars-Sinai Ventures | Public page/news source; verify tenure, reporting lines and references |
| Founders/researchers/technologists/clinicians | Team composition described by company | Public page/news source; verify tenure, reporting lines and references |
VII.D Compensation arrangements
not publicly verifiable confidence: low
Personnel or hiring signals are visible, but org chart, headcount history, turnover, compensation and key-person risk are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Compensation arrangements.
VII.E Incentive stock plans
not publicly verifiable confidence: low
Personnel or hiring signals are visible, but org chart, headcount history, turnover, compensation and key-person risk are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Incentive stock plans.
VII.F Significant employee relations problems, past or present
unverified confidence: medium
Personnel or hiring signals are visible, but org chart, headcount history, turnover, compensation and key-person risk are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Significant employee relations problems, past or present.
VII.G Personnel Turnover
unverified confidence: medium
Personnel or hiring signals are visible, but org chart, headcount history, turnover, compensation and key-person risk are private.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Personnel Turnover.
08Legal and Related Matters
Public legal/IP/regulatory information is incomplete; counsel should verify litigation, IP ownership, compliance, insurance and contracts.
VIII.A Pending lawsuits against the Company
unverified confidence: medium
Public legal/IP/regulatory information is incomplete; counsel should verify litigation, IP ownership, compliance, insurance and contracts.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Pending lawsuits against the Company.
VIII.B Pending lawsuits initiated by Company
unverified confidence: medium
Public legal/IP/regulatory information is incomplete; counsel should verify litigation, IP ownership, compliance, insurance and contracts.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Pending lawsuits initiated by Company.
VIII.C Environmental and employee safety issues and liabilities
unverified confidence: medium
Public legal/IP/regulatory information is incomplete; counsel should verify litigation, IP ownership, compliance, insurance and contracts.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Environmental and employee safety issues and liabilities.
VIII.D Material patents, copyrights, licenses, and trademarks
partially verified confidence: medium
Public legal/IP/regulatory information is incomplete; counsel should verify litigation, IP ownership, compliance, insurance and contracts.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Material patents, copyrights, licenses, and trademarks.
| matter | public evidence | diligence request |
|---|---|---|
| Patent | CB Insights lists 1 filed patent with a 2024 grant | Counsel review and primary documents required |
| Healthcare regulatory exposure | HIPAA, FDA, payer, provider and state-licensing risk may sit in portfolio | Counsel review and primary documents required |
| Contracts/insurance/litigation | Health-system, LP/fund and portfolio contracts require counsel review | Counsel review and primary documents required |
VIII.E Insurance coverage and material exposures
not publicly verifiable confidence: low
Public legal/IP/regulatory information is incomplete; counsel should verify litigation, IP ownership, compliance, insurance and contracts.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Insurance coverage and material exposures.
VIII.F Material contracts
not publicly verifiable confidence: low
Public legal/IP/regulatory information is incomplete; counsel should verify litigation, IP ownership, compliance, insurance and contracts.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Material contracts.
VIII.G Regulatory agency problems
partially verified confidence: medium
Public legal/IP/regulatory information is incomplete; counsel should verify litigation, IP ownership, compliance, insurance and contracts.
Evidence gaps
- Private records, third-party confirmations and specialist review are required for checklist items not disclosed publicly.
Hidden risks
- Material private-data gaps remain until company records are reviewed.
Follow-up questions
- Provide primary source documents for Regulatory agency problems.
| risk id | risk title | category | severity | likelihood |
|---|---|---|---|---|
| R-001 | Studio economics and portfolio valuation opacity | financial | high | unknown |
| R-002 | Healthcare regulatory and clinical-liability dispersion | regulatory | high | medium |
| R-003 | Partner-logo dependency and concentration risk | customer | medium | medium |
| R-004 | AI venture thesis execution risk | market | medium | medium |
Evidence
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | Redesign Health was selected from a current CB Insights unicorn-list row at $1.70B. | verified medium | SRC-001 |
| EC-002 | Redesign Health has an active public company profile and operating status signal. | verified medium | SRC-002 |
| EC-003 | Redesign Health's public valuation and financing evidence is incomplete but supports unicorn screening. | partially verified medium | SRC-001SRC-006 |
| EC-004 | Redesign Health publicly markets active products or services. | verified medium | SRC-003SRC-005 |
| EC-005 | Redesign Health has public customer, partner or scale signals. | partially verified medium | SRC-003SRC-004 |
| EC-006 | Redesign Health operates in a competitive market with identifiable alternatives. | verified medium | SRC-002 |
| EC-007 | Redesign Health's GTM motion is visible only at public channel level. | partially verified medium | SRC-003 |
| EC-008 | Redesign Health has public R&D, technology, data or IP signals. | partially verified medium | SRC-002SRC-005 |
| EC-009 | Redesign Health has public personnel or hiring signals but no complete org chart. | partially verified medium | SRC-004SRC-005 |
| EC-010 | Redesign Health's material legal, regulatory, insurance and contract posture is not fully public. | not publicly verifiable low | SRC-002SRC-007 |
| EC-011 | Private diligence is required for Redesign Health's financial quality, customer concentration and contract terms. | not publicly verifiable low | SRC-001SRC-002 |
| EC-012 | Redesign Health has current operating signals from recent public pages, news, careers or profile status. | verified medium | SRC-002SRC-004 |
| ID | Publisher | Title | Accessed |
|---|---|---|---|
| SRC-001 | CB Insights | CB Insights complete unicorn list | 2026-05-28 |
| SRC-002 | CB Insights | Redesign Health profile | 2026-05-28 |
| SRC-003 | Redesign Health | Redesign Health homepage | 2026-05-28 |
| SRC-004 | Redesign Health | Redesign Health companies page | 2026-05-28 |
| SRC-005 | Redesign Health | Redesign Health careers page | 2026-05-28 |
| SRC-006 | MobiHealthNews | MobiHealthNews funding article | 2026-05-28 |
| SRC-007 | DuckDuckGo snippets | Redesign Health funding search result | 2026-05-28 |
| SRC-008 | CB Insights / LA Business Journal excerpt | Cedars-Sinai collaboration excerpt | 2026-05-28 |
Disclaimer
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.